Purpose: To describe the first use of the bispecific monoclonal antibody faricimab for sarcoid uveitis with refractory cystoid macular edema (CME). Methods: A single case was evaluated. Results: An 82-year-old woman presented with blurred vision and signs of sarcoid uveitis bilaterally, including swollen optic discs with disc nodules, CME with chorioretinal peripheral lesions in the right eye and segmental periphlebitis in the left eye. Treatment with intravitreal faricimab was initiated after systemic and topical prednisolone and oral ibuprofen failed. Significant improvement in the patient’s best-corrected visual acuity and central subfield thickness was seen after 2 faricimab injections. Optical coherence tomography showed resolution of the intraretinal cyst and CME. Color fundus photography also showed improvement in the optic disc swelling and resolution of the retinal macroaneurysm. Conclusions: Faricimab can be a promising treatment for refractory CME in patients with sarcoid uveitis.
NiedererRLMaSPWilsherML, et al. Systemic associations of sarcoid uveitis: correlation with uveitis phenotype and ethnicity. Am J Ophthalmol. 2021;229:169-175.
3.
BowlingBKanskiJJ. Kanski’s Clinical Ophthalmology: A Systematic Approach. Elsevier; 2016.
4.
MochizukiMSmithJRTakaseHKaburakiTAcharyaNRRaoNA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418-1422.
5.
BienvenuFHTiffetTMaucort-BoulchD, et al. Factors associated with ocular and extraocular recovery in 143 patients with sarcoid uveitis. J Clin Med. 2020;9(12):3894.
6.
RothovaA. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000;84(1):110-116.
7.
KabaselePMTaylorSRLightmanSL. Causes of visual loss in uveitis. Invest Ophthalmol Vis Sci. 2011;52(14):2728-2728.
OyeniranEBhandariSSenHNKodatiS. Treatment outcomes of anti-VEGF agents for non-infectious uveitic macula edema. Invest Ophthalmol Vis Sci. 2022;63(7):3210–A0436.
10.
KoronisSStavrakasPBalidisMKozeisNTranosPG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667-680.
11.
NicolòMFerro DesideriLVaggeATraversoCE. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30(3):193-200.
12.
JoussenAMRicciFParisLPKornCQuezada-RuizCZarbinM. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35(5):1305-1316.
13.
IwataDLundh von LeithnerPNgYSEHartmannGShimaDT. Anti -VEGF/Ang2 bi-specific antibody ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2014;55(13):2354-2354.
14.
RegulaJTLundh von LeithnerPFoxtonR, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265-1288.
15.
Cordero ComaMSobrinLOnalSChristenWFosterCS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114(8):1574-1579.e1.
16.
KarimRSykakisELightmanSFraser-BellS. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109-1144.
17.
GulatiNForooghianFLiebermanRJabsDA. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol. 2011;95(2):162-165.
18.
CarvalheiroTLopesAPvan der KroefM, et al. Angiopoietin-2 promotes inflammatory activation in monocytes of systemic sclerosis patients. Int J Mol Sci. 2020;21(24):9544.
19.
TodeJRichertEKoinzerS, et al. Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine. 2017;96:8-15.
20.
SuzukiKIwataDNambaK, et al. Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis. PLoS One. 2023;18(11):e0294745.
21.
PalmieriFYounisSBedan HamoudAFabozziL. Uveitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflamm. 2024;32(8):1873-1877.
